Compare Oscar Health Inc (OSCR) vs Pfizer Inc (PFE) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.